Laboratory study
|
42727. Léonard A, Gerber GB. Mutagenicity, carcinogenicity and teratogenicity of
antimony compounds. Mutat Res 1996; 366:1-8.
28. Paumgartten FJ, Chahoud I. Embryotoxicity of meglumine antimoniate in the rat.
Reprod Toxicol 2001; 15:327-331.-2929. Miranda ES, Miekeley N, De-Carvalho RR, Paumgartten FJ. Developmental toxicity
of meglumine antimoniate and transplacental transfer of antimony in the rat. Reprod Toxicol 2006;
21:292-300.3737. Dorlo TP, van Thiel PP, Huitema AD, Keizer RJ, Vries HJ, Beijnen JH, et al.
Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents
Chemother 2008; 52:2855-2860.
|
NA |
14040. Cruz A, Rainey PM, Herwaldt BL, Stagni G, Palacios R, Trujillo R, et al.
Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J
Infect Dis 2007; 195:602-608.
|
NA |
16767. Bernardo JF, Murakami S, Branch RA, Sabra R. Potassium depletion potentiates
amphotericin-B-induced toxicity to renal tubules. Nephron 1995; 70:235-241.
|
NA |
27373. Kan VL, Bennett JE, Amantea MA, Smolskis MC, McManus E, Grasela DM, et al.
Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin
B desoxycholate in healthy male volunteers. J Infect Dis 1991; 164:418-421.7474. Unger C, Fleer E, Damenz W, Hilgard P, Nagel G, Eibl H. Hexadecylphosphocholine:
determination of serum concentrations in rats. J Lipid Mediat 1991; 3:71-78.
|
17777. Murray HW. Suppression of posttreatment recurrence of experimental visceral
Leishmaniasis in T-cell-deficient mice by oral miltefosine. Antimicrob Agents Chemother 2000;
44:3235-3236.
|
9 |
Case reports |
32424. Figueiró-Filho EA, El Beitune P, Queiroz GT, Somensi RS, Morais NO,
Dorval ME, et al. Visceral leishmaniasis and pregnancy: analysis of cases reported in a
central-western region of Brazil. Arch Gynecol Obstet 2008; 278:13-16.3030. Morgan DJ, Guimaraes LH, Machado PR, D'Oliveira A, Almeida RP, Lago EL, et
al. Cutaneous leishmaniasis during pregnancy: exuberant lesions and potential fetal complications.
Clin Infect Dis 2007; 45:478-482.3131. Silveira BP, Araújo Sobrinho J, Leite LF, Sales MN, Gouveia MS, Mathias
RL, et al. Premature birth after the use of pentavalent antimonial: case report. Rev Soc Bras Med
Trop 2003; 36:523-525.
|
NA |
44444. Garcerant D, Rubiano L, Blanco V, Martinez J, Baker NC, Craft N. Possible links
between sickle cell crisis and pentavalent antimony. Am J Trop Med Hyg 2012;
86:1057-1061.4646. Campos-Muñoz L, Quesada-Cortés A, Martín-Díaz MA,
Rubio-Flores C, Lucas-Laguna R. Leishmania braziliensis: report of a pediatric imported case with
response to liposomal amphotericin B. Actas Dermosifiliogr 2007; 98:42-44.
47. Rosal T, Artigao FB, Miguel MJ, Lucas R, Castillo F. Successful treatment of
childhood cutaneous leishmaniasis with liposomal amphotericin B: report of two cases. J Trop Pediatr
2010; 56:122-124.-4848. Sampaio RN, Paula CD. American cutaneous leishmaniasis in the Federal District.
Rev Soc Bras Med Trop 1999; 32:523-528.
|
15959. Neumayr AL, Walter C, Stoeckle M, Braendle N, Glatz K, Blum JA. Successful
treatment of imported mucosal Leishmania infantum leishmaniasis with miltefosine after severe
hypokalemia under meglumine antimoniate treatment. J Travel Med 2012; 19:124-126.
|
36161. Brostoff JM, Lockwood DN. Glucocorticoids as a novel approach to the treatment
of disabling side effects of sodium stibogluconate. J Clin Pharm Ther 2012;
37:122-123.6262. Amato VS, Rabello A, Rotondo-Silva A, Kono A, Maldonado TP, Alves IC, et al.
Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two
immunocompromised patients. Acta Trop 2004; 92:127-132.6868. Zea DF, Prager M, Figueroa RA, Miranda MC. Mucosal complication of cutaneous
leishmaniasis. Biomédica 2009; 29:9-11.
|
26161. Brostoff JM, Lockwood DN. Glucocorticoids as a novel approach to the treatment
of disabling side effects of sodium stibogluconate. J Clin Pharm Ther 2012;
37:122-123.7272. Eryilmaz A, Durdu M, Baba M, Bal N, Yiğit F. A case with two unusual
findings: cutaneous leishmaniasis presenting as panniculitis and pericarditis after antimony
therapy. Int J Dermatol 2010; 49:295-297.
|
NA |
306262. Amato VS, Rabello A, Rotondo-Silva A, Kono A, Maldonado TP, Alves IC, et al.
Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two
immunocompromised patients. Acta Trop 2004; 92:127-132.7575. Machado ES, Braga MP, Cruz AM, Coutinho SG, Vieira AR, Rutowitsch MS, et al.
Disseminated American muco-cutaneous leishmaniasis caused by Leishmania braziliensis braziliensis in
a patient with AIDS: a case report. Mem Inst Oswaldo Cruz 1992; 87:487-492.7676. Amato VS, Nicodemo AC, Amato JG, Boulos M, Amato-Neto V. Mucocutaneous
leishmaniasis associated with HIV infection treated successfully with liposomal amphotericin B
(AmBisome). J Antimicrob Chemother 2000; 46:341-342.7878. Sampaio RN, Salaro CP, Resende P, de Paula CD. American cutaneous leishmaniasis
associated with HIV/AIDS: report of four clinical cases. Rev Soc Bras Med Trop 2002;
35:651-654.7979. Puig L, Pradinaud R. Leishmania and HIV co-infection: dermatological
manifestations. Ann Trop Med Parasitol 2003; 97 (suppl I):107-114.8282. Posada-Vergara MP, Lindoso JA, Tolezano JE, Pereira-Chioccola VL, Silva MV, Goto
H. Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2
patients with AIDS. J Infect Dis 2005; 192:1819-1822.
83. Schraner C, Hasse B, Hasse U, Baumann D, Faeh A, Burg G, et al. Successful
treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised
patient infected with HIV-1. Clin Infect Dis 2005; 40:e120-124.
84. Sinha S, Fernández G, Kapila R, Lambert WC, Schwartz RA. Diffuse
cutaneous leishmaniasis associated with the immune reconstitution inflammatory syndrome. Int J
Dermatol 2008; 47:1263-1270.
85. Chrusciak-Talhari A, Ribeiro-Rodrigues R, Talhari C, Silva RM, Ferreira LC,
Botileiro SF, et al. Tegumentary leishmaniasis as the cause of immune reconstitution inflammatory
syndrome in a patient co-infected with human immunodeficiency virus and Leishmania guyanensis. Am J
Trop Med Hyg 2009; 81:559-564.
86. Lindoso JA, Barbosa RN, Posada-Vergara MP, Duarte MI, Oyafuso LK, Amato VS, et
al. Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World. Br J
Dermatol 2009; 160:311-318.
87. Torrico F, Parrado R, Castro R, Marquez CJ, Torrico MC, Solano M, et al.
Co-Infection of Leishmania (Viannia) braziliensis and HIV: report of a case of mucosal
leishmaniasis in Cochabamba, Bolivia. Am J Trop Med Hyg 2009; 81:555-558.
88. Soni P, Prasad N, Khandelwal K, Ghiya BC, Mehta RD, Bumb RA, et al. Unresponsive
cutaneous leishmaniasis and HIV co-infection: report of three cases. Indian J Dermatol Venereol
Leprol 2011; 77:251.
89. Gontijo CM, Pacheco RS, Orefice F, Lasmar E, Silva ES, Melo MN. Concurrent
cutaneous, visceral and ocular leishmaniasis caused by Leishmania (Viannia) braziliensis
in a kidney transplant patient. Mem Inst Oswaldo Cruz 2002; 97:751-753.
90. Mirzabeigi M, Farooq U, Baraniak S, Dowdy L, Ciancio G, Vincek V. Reactivation
of dormant cutaneous Leishmania infection in a kidney transplant patient. J Cutan Pathol 2006;
33:701-704.-9191. Ozcan D, Seçkin D, Allahverdiyev AM, Weina PJ, Aydin H, Ozçay F,
et al. Liver transplant recipient with concomitant cutaneous and visceral leishmaniasis. Pediatr
Transplant 2007; 11:228-232.9393. Zandieh A, Zandieh B, Dastgheib L. Dissemination of localized cutaneous
leishmaniasis in an organ transplant recipient: case report and literature review. Int J Dermatol
2013; 52:59-62.
94. Muñoz P, Valerio M, Puga D, Bouza E. Parasitic infections in solid organ
transplant recipients. Infect Dis Clin North Am 2010; 24:461-495.
95. Ponticelli C, Bencini PL. Nonneoplastic mucocutaneous lesions in organ
transplant recipients. Transpl Int 2011; 24:1041-1050.
96. Saha M, Shipley D, McBride S, Kennedy C, Vega-Lopez F. Atypical cutaneous
leishmaniasis in two patients receiving low-dose methotrexate. Br J Dermatol 2006;
155:830-833.
97. Tuon FF, Sabbaga Amato V, Floeter-Winter LM, Andrade Zampieri R, Amato Neto V,
Siqueira França FO, et al. Cutaneous leishmaniasis reactivation 2 years after treatment
caused by systemic corticosteroids - first report. Int J Dermatol 2007; 46:628-630.-9898. Pitini V, Cascio A, Arrigo C, Altavilla G. Visceral leishmaniasis after
alemtuzumab in a patient with chronic lymphocytic leukaemia. Br J Haematol 2012;
156:1.103103. Amato VS, Tuon FF, Camargo RA, Souza RM, Santos CR, Nicodemo AC. Can we use a
lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis? Am J
Trop Med Hyg 2011; 85:818-819.107107. Simon I, Wissing KM, Del Marmol V, Antinori S, Remmelink M, Nilufer Broeders E,
et al. Recurrent leishmaniasis in kidney transplant recipients: report of 2 cases and systematic
review of the literature. Transpl Infect Dis 2011; 13:397-406.
108. Bacha MM, Abderrahim E, Ounissi M, Chaouech D, Cherif M, Turki S, et al.
Association of post-transplant lymphoproliferative disease and visceral leishmaniasis after kidney
transplantation. Nephrol Ther 2011; 7:488-493.
109. Postorino MC, Bellantoni M, Catalano C, Caridi G, Rosa M, Seck S, et al.
Visceral leishmaniasis reactivation in transplant patients: a minireview with report of a new case.
J Nephrol 2011; 24:530-534.
110. Boletis JN, Pefanis A, Stathakis C, Helioti H, Kostakis A, Giamarellou H.
Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal
amphotericin B (AmBisome). Clin Infect Dis 1999; 28:1308-1309.
111. Bousquet E, Mura F, Villain M, Rivière S, Konate A, Schneider C.
Infectious complications in patients treated with anti-TNF-alpha: two cases of leishmaniasis. J Fr
Ophtalmol 2012; 35:695-699.
112. Prokopakis EP, Panagiotaki IE, Papadakis IA, Vardouniotis AS, Lagoudianakis GM,
Velegrakis GA. Immunocompromised patient with an ulcerated nasolabial skin lesion. BMJ 2010;
340:c1444.
113. Veroux M, Corona D, Giuffrida G, Cacopardo B, Sinagra N, Tallarita T, et al.
Visceral leishmaniasis in the early post-transplant period after kidney transplantation: clinical
features and therapeutic management. Transpl Infect Dis 2010; 12:387-391.-114114. Frapier JM, Abraham B, Dereure J, Albat B. Fatal visceral leishmaniasis in a
heart transplant recipient. J Heart Lung Transplant 2001; 20:912-913.
|
42 |
Case series
|
22525. Pagliano P, Carannante N, Rossi M, Gramiccia M, Gradoni L, Faella FS, et al.
Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. J
Antimicrob Chemother 2005; 55:229-233.2626. Mueller M, Balasegaram M, Koummuki Y, Ritmeijer K, Santana MR, Davidson R. A
comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral
leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother 2006; 58:811-815.
|
NA |
14545. Gadelha AR, Oliveira WC, Assunção IJ, Dourado HV. Tratamento da
leishmaniose tegumentar americana com injeções intralesionais de n-metil-glucamina. An
Bras Dermatol 1990; 65:201.
|
35454. Vasconcellos ECF, Schubach AO, Valete-Rosalino CM, Coutinho RS,
Conceição-Silva F, Salgueiro MM, et al. American tegumentary leishmaniasis in older
adults: 44 cases treated with an intermittent low-dose antimonial schedule in Rio de Janeiro,
Brazil. J Am Geriatr Soc 2010; 58:614-616.5757. Vasconcellos EC, Pimentel MI, Schubach AO, Oliveira RV, Azeredo-Coutinho RB,
Silva FC, et al. Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis
patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006). Am
J Trop Med Hyg 2012; 87:257-260.5858. Wise ES, Armstrong MS, Watson J, Lockwood DN. Monitoring toxicity associated
with parenteral sodium stibogluconate in the day-case management of returned travellers with New
World cutaneous leishmaniasis [corrected]. PLoS Negl Trop Dis 2012;
6:e1688.
|
- |
NA |
NA |
38181. Sindermann H, Engel KR, Fischer C, Bommer W, Program MCU. Oral miltefosine for
leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection.
Clin Infect Dis 2004; 39:1520-1523.9999. Guerra JA, Coelho LI, Pereira FR, Siqueira AM, Ribeiro RL, Almeida TM, et al.
American tegumentary leishmaniasis and HIV-AIDS association in a tertiary care center in the
Brazilian Amazon. Am J Trop Med Hyg 2011; 85:524-527.102102. Alexandrino-de-Oliveira P, Santos-Oliveira JR, Dorval ME, Da-Costa F, Pereira
GR, Cunha RV, et al. HIV/AIDS-associated visceral leishmaniasis in patients from an endemic area
in Central-west Brazil. Mem Inst Oswaldo Cruz 2010; 105:692-697.
|
9 |
Case-control study |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
18080. Couppié P, Clyti E, Sobesky M, Bissuel F, Del Giudice P, Sainte-Marie D,
et al. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus
(HIV)-infected patients and non-HIV-infected patients in French Guiana. Br J Dermatol
2004; 151:1165-1171.
|
1 |
Cohort study |
23232. Adam GK, Abdulla MA, Ahmed AA, Adam I. Maternal and perinatal outcomes of
visceral leishmaniasis (kala-azar) treated with sodium stibogluconate in eastern Sudan.
Int J Gynaecol Obstet 2009; 107:208-210.3838. Dorlo TP, Balasegaram M, Lima MA, Vries PJ, Beijnen JH, Huitema AD.
Translational pharmacokinetic modelling and simulation for the assessment of duration of
contraceptive use after treatment with miltefosine. J Antimicrob Chemother 2012;
67:1996-2004.
|
NA |
14343. Layegh P, Khademi Z, Kiafar B. Side effects of systemic meglumine antimoniate in
children with cutaneo us leishmaniasis: A prospective clinico-laborator y assess. Euro J Pediatric
Dermatol 2012; 22:15.
|
45252. Diniz DS, Costa AS, Escalda PM. The effect of age on the frequency of adverse
reactions caused by antimony in the treatment of American tegumentary leishmaniasis in Governador
Valadares, State of Minas Gerais, Brazil. Rev Soc Bras Med Trop 2012; 45:597-600.5353. Araujo-Melo MH, Meneses AM, Schubach AO, Moreira JS,
Conceição-Silva F, Salgueiro MM, et al. Risk factors associated with dizziness during
treatment of mucosal leishmaniasis with meglumine antimoniate: 16-year retrospective study of cases
from Rio de Janeiro, Brazil. J Laryngol Otol 2010; 124:1056-1060.5555. Rodrigues AM, Hueb M, Nery AF, Fontes CJ. Possible cardioprotective effect of
angiotensin-converting enzyme inhibitors during treatment of American tegumentary leishmaniasis with
meglumine antimoniate. Acta Trop 2007; 102:113-118.5656. Esfandiarpour I, Farajzadeh S, Rahnama Z, Fathabadi EA, Heshmatkhah A. Adverse
effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters
in the treatment of cutaneous leishmaniasis. Int J Dermatol 2012; 51:1221-1225.
|
36060. Oliveira RA, Lima CG, Mota RM, Martins AM, Sanches TR, Seguro AC, et al. Renal
function evaluation in patients with American cutaneous leishmaniasis after specific treatment with
pentavalent antimonial. BMC Nephrol 2012; 13:44.6363. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The epidemiology of
nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001;
111:528-534.6464. Oliveira MJ, Silva Júnior GB, Abreu KL, Rocha NA, Garcia AV, Franco LF,
et al. Risk factors for acute kidney injury in visceral leishmaniasis (Kala-Azar). Am J
Trop Med Hyg 2010; 82:449-453.
|
17171. Sadeghian G, Ziaei H, Sadeghi M. Electrocardiographic changes in patients with
cutaneous leishmaniasis treated with systemic glucantime. Ann Acad Med Singapore 2008;
37:916-918.
|
NA |
- |
11 |
Narrative review
|
62222. Njoku J, Gumeel D, Hermsen E. Antifungal Therapy in Pregnancy and Breastfeeding.
Current Fungal Infection Reports. 2010; 4:62-69.2323. Dean JL, Wolf JE, Ranzini AC, Laughlin MA. Use of amphotericin B during
pregnancy: case report and review. Clin Infect Dis 1994; 18:364-368.3333. Ameen M. Cutaneous and mucocutaneous leishmaniasis: emerging therapies and
progress in disease management. Expert Opin Pharmacother 2010; 11:557-569.
34. Minodier P, Jurquet AL, Noël G, Uters M, Laporte R, Garnier JM.
Leishmaniasis treatment. Arch Pediatr 2010; 17:838-839.
35. Shukla AK, Singh BK, Patra S, Dubey VK. Rational approaches for drug designing
against leishmaniasis. Appl Biochem Biotechnol 2010; 160:2208-2218.-3636. Sindermann H, Engel J. Development of miltefosine as an oral treatment for
leishmaniasis. Trans R Soc Trop Med Hyg 2006; 100 (suppl I):17-20.
|
NA |
15151. Berman J. Current treatment approaches to leishmaniasis. Curr Opin Infect Dis
2003;16:397-401.
|
NA |
17070. Clementi A, Battaglia G, Floris M, Castellino P, Ronco C, Cruz DN. Renal
involvement in leishmaniasis: A review of the literature. NDT Plus 2011; 4:147-152.
|
NA |
NA |
69292. Antinori S, Schifanella L, Corbellino M. Leishmaniasis: new insights from an old
and neglected disease. Eur J Clin Microbiol Infect Dis 2012; 31:109-118.9494. Muñoz P, Valerio M, Puga D, Bouza E. Parasitic infections in solid organ
transplant recipients. Infect Dis Clin North Am 2010; 24:461-495.100100. Amerson EH, Maurer TA. Immune reconstitution inflammatory syndrome and tropical
dermatoses. Dermatol Clin 2011; 29:39-43.101101. Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet JP, et al.
The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008;
21:334-359.106106. Kotton CN, Lattes R, Practice AIDCo. Parasitic infections in solid organ
transplant recipients. Am J Transplant. 2009; 9 (suppl IV):234-251.115115. Sindermann H, Croft SL, Engel KR, Bommer W, Eibl HJ, Unger C, et al.
Miltefosine (Impavido): the first oral treatment against leishmaniasis. Med Microbiol
Immunol 2004; 193:173-180.
|
14 |
Systematic review |
NA |
NA |
- |
NA |
299. Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzochi MC, et al.
Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta
Trop 2011; 118:87-96.6565. Mistro S, Maciel IM, Menezes RG, Maia ZP, Schooley RT, Badaró R. Does
lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin
Infect Dis 2012; 54:1774-1777.
|
199. Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzochi MC, et al.
Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta
Trop 2011; 118:87-96.
|
199. Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzochi MC, et al.
Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta
Trop 2011; 118:87-96.
|
1107107. Simon I, Wissing KM, Del Marmol V, Antinori S, Remmelink M, Nilufer Broeders E,
et al. Recurrent leishmaniasis in kidney transplant recipients: report of 2 cases and systematic
review of the literature. Transpl Infect Dis 2011; 13:397-406.
|
5 |
Clinical trial |
NA |
NA |
61616. Machado PR, Ampuero J, Guimarães LH, Villasboas L, Rocha AT, Schriefer A,
et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in
Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 2010; 4:e912.1717. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, Silva RM, Gadelha Yamashita
EP, Oliveira Penna G, et al. Randomized controlled clinical trial to access efficacy and safety of
Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia)
guyanensis in Manaus, Brazil. Am J Trop Med Hyg 2011; 84:255-260.4141. Layegh P, Rahsepar S, Rahsepar AA. Systemic meglumine antimoniate in acute
cutaneous leishmaniasis: children versus adults. Am J Trop Med Hyg 2011;
84:539-542.4242. Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treatment failure in children in a
randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis
due to Leishmania viannia species. Am J Trop Med Hyg 2001; 64:187-193.4949. Neves LO, Talhari AC, Gadelha EP, Silva Júnior RM, Guerra JA, Ferreira
LC, et al. A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin
B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis. An Bras Dermatol 2011;
86:1092-1101.5050. Rubiano LC, Miranda MC, Muvdi Arenas S, Montero LM, Rodríguez-Barraquer
I, Garcerant D, et al. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous
leishmaniasis in children. J Infect Dis 2012; 205:684-692.
|
NA |
16666. Echevarria J, Seas C, Cruz M, Chávez E, Campos M, Cieza J, et al. Oral
rehydration solution to prevent nephrotoxicity of amphotericin B. Am J Trop Med Hyg 2006;
75:1108-1112.
|
NA |
NA |
1104104. Soto J, Soto P. Oral miltefosine to treat leishmaniasis. Biomedica 2006; 26
(suppl I):207-217.
|
8 |
Total |
17 |
0 |
14 |
8 |
11 |
4 |
3 |
42|| |
- |